This hypothesis is supported by evidence comparing serum GFAP levels of intracerebral haemorrhage patients, who experience rapid blood–brain barrier disruption, to ischaemic stroke patients, where the opening of the blood–brain barrier occurs more gradually (Dvorak et al., 2009). The gene discussed is GFAP; the disease is intracerebral hemorrhage.